Drug Information

Drug (ID: DG00943) and It's Reported Resistant Information

• Name: Iopamidol
• Synonyms: Iopamidol; 60166-93-0; Iopamiron; Iopamiro; Isovue; Niopam; Solutrast; Gastromiro; Iopamidolum; B-15000; UNII-JR13W81H44; SQ-13396; 62883-00-5; (S)-N,N'-bis(2-Hydroxy-1-(hydroxymethyl)ethyl)-2,4,6-triiodo-5-lactamidoisophthalamide; L-(+)-N,N'-Bis(2-hydroxy-1-hydroxymethylethyl)-2,4,6-triiodo-5-lactamide isophthalamide; L-5alpha-Hydroxypropionylamino-2,4,6-triiodoisophthalic acid di(1,3-dihydroxy-2-propylamide); SQ 13,396; CHEBI:31711; JR13W81H44; Iopamidol 300; Solutrast 370; iomapidol; NCGC00016892-01; Oypalomin; Isovue 370; CAS-60166-93-0; DSSTox_CID_3158; (S)-N1,N3-bis(1,3-dihydroxypropan-2-yl)-5-(2-hydroxypropanamido)-2,4,6-triiodoisophthalamide; DSSTox_RID_76896; DSSTox_GSID_23158; 1-N,3-N-bis(1,3-dihydroxypropan-2-yl)-5-[[(2S)-2-hydroxypropanoyl]amino]-2,4,6-triiodobenzene-1,3-dicarboxamide; Iopamiron 300; Iopamiron 370; Jopamiron 200; Iopamiro 370; Isovue-370; Niopam 300; Iopamidolum [INN-Latin]; N,N'-bis(1,3-dihydroxypropan-2-yl)-5-{[(2S)-2-hydroxypropanoyl]amino}-2,4,6-triiodobenzene-1,3-dicarboxamide; Iopamidol-200; Iopamidol-250; Iopamidol-300; Iopamidol-370; Scanlux-300; Scanlux-370; Isovue-128; Isovue-200; Isovue-250; Isovue-300; Isovue-M 200; Isovue-M 300; EINECS 262-093-6; B 15000; BRN 6250226; Iopamyron; SQ 13396; HSDB 8075; (S)-N,N'-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-5-lactamidoisophthalamide; Iopamiron (TN); Iopamidol-200 in plastic container; Iopamidol-250 in plastic container; Iopamidol-300 in plastic container; Iopamidol-370 in plastic container; Isovue (TN); Iopamidol [USAN:USP:INN:BAN:JAN]; Prestwick0_000871; Prestwick1_000871; Prestwick2_000871; Prestwick3_000871; Iopamidol (JP17/USP); L-5alpha-Idrossipropionilamino-2,4,6-triiodoisoftal-di(1,3-diidrossi-2-propilamide); SCHEMBL27781; BSPBio_000941; SPBio_002862; BPBio1_001037; CHEMBL1200932; DTXSID1023158; HMS1570P03; HMS2097P03; HMS3714P03; Pharmakon1600-01502304; ACT03261; HY-B0684; ZINC3830947; Tox21_110668; NSC759636; s4532; AKOS015891034; Tox21_110668_1; CCG-213024; DB08947; KS-1421; NCGC00016892-02; NCGC00016892-04; (S)-N,N'-Bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodoisophthaldiamide; 1,3-Benzenedicarboxamide, N,N'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-(((2S)-2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodo-; 1,3-Benzenedicarboxamide, N,N'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodo-, (S)-; AB00513941; D01797; H11976; hydroxypropanamido)-2,4,6-triiodoisophthalamide; AB00513941_02; 166I930; A834067; Q424788; Q-201245; (S)-N1,N3-bis(1,3-dihydroxypropan-2-yl)-5-(2-; BRD-K75868704-001-01-2; (S)-N,N inverted exclamation marka-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-5-lactamidoisophthalamide; (S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide; N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-{[(2S)-2-hydroxypropanoyl]amino}-2,4,6-triiodobenzene-1,3-dicarboxamide; N1,N3-bis(1,3-dihydroxypropan-2-yl)-5-(2-hydroxypropanoylamino)-2,4,6-triiodo-benzene-1,3-dicarboxamide; N1,N3-bis(1,3-dihydroxypropan-2-yl)-5-[(2S)-2-hydroxypropanamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
• Indication:
  In total 1 Indication(s)
  Cardiovascular disease [ICD-11: BA00-BE2Z]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Multiple myeloma [ICD-11: 2A83]; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: C17H22I3N3O8
• IsoSMILES: C[C@@H](C(=O)NC1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O
• InChI: 1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1
• InChIKey: XQZXYNRDCRIARQ-LURJTMIESA-N
• PubChem CID: 65492
• ChEBI ID: CHEBI:31711
• TTD Drug ID: D0O2HQ
• DrugBank ID: DB08947

Type(s) of Resistant Mechanism of This Drug

  RTDM: Regulation by the Disease Microenvironment

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Multiple myeloma [ICD-11: 2A83]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Regulation by the Disease Microenvironment (RTDM)

Key Molecule: Solute carrier family 2, facilitated glucose transporter member 1 (Glucose transporter type 1, erythrocyte/brain) (GLUT-1) (GT1) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Multiple myeloma [ICD-11: 2A83.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: NCI-H508 cells; Colon; Homo sapiens (Human); CVCL_1564
• In Vivo Model: Orthotopic BM engrafted MM xenograft model; Mus musculus
• Experiment for Molecule Alteration: Immunohistochemistry and histologic analysis
• Experiment for Drug Resistance: Micro-Computed Tomography; Positron emission tomography; Magnetic resonance spectroscopy; Magnetic resonance imaging (MRI)
• Mechanism Description: Adaptive responses to hypoxia may be an essential element in MM progression and drug resistance. This metabolic adaptation involves a decrease in extracellular pH (pHe), and it depends on the upregulation of glucose transporters (GLUTs) that is common in hypoxia and in cancer cells.

References

• Ref 1: AcidoCEST MRI Evaluates the Bone Microenvironment in Multiple Myeloma .Mol Imaging Biol. 2021 Dec;23(6):865-873. doi: 10.1007/s11307-021-01611-2. Epub 2021 May 3. 10.1007/s11307-021-01611-2